▲ +∞ Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Aduro Biotech in the last 3 months. The average price target is $3.75, with a high forecast of $3.75 and a low forecast of $3.75. The average price target represents a ∞ upside from the last price of $0.00.
The current consensus among 2 investment analysts is to buy stock in Aduro Biotech. This rating has held steady since November 2020, when it changed from a Hold consensus rating.
Chinook Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering, developing, and commercializing precision medicines for rare, severe chronic kidney diseases. The company was founded in 2019 and is headquartered in Seattle, WA.